MELOXIDYL

Meloxicam

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Cox Inhibitory, Nonsteroidal Anti-Inflammatory, Pain Reliever

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Osteoarthritis, Rheumatoid Arthritis, Spondylitis, Spondyloarthritis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of MELOXIDYL

Quick Facts

Property	Description
Active ingredient	Meloxicam
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin / Status	Synthetic, Oxicam derivative, Prescription-only (Rx)
Forms (High-level)	Tablet, Oral Suspension, Injectable Solution
General purpose	Relief from inflammation, pain, and fever

What Type of Medicine is MELOXIDYL and What is it Made Of?

MELOXIDYL is a proprietary, synthetic medication whose therapeutic action relies solely on the active ingredient, Meloxicam (INN). Meloxicam is classified within the major pharmacological group of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), specifically belonging to the Oxicam derivative subclass. This designation confirms its non-natural origin and its distinct chemical structure as a specialized NSAID.

A key characteristic that differentiates the Meloxicam component is its function as a preferential COX-2 inhibitor, a mechanism recognized in pharmacological studies. The specific chemical identity of Meloxicam is highly documented, anchoring its predictable systemic effect when administered as a single-agent product.

How Does MELOXIDYL Help the Body Generally?

The fundamental action of MELOXIDYL is to modulate the body’s inflammatory response, aiming to mitigate core symptoms such as swelling and discomfort. Its mechanism limits the synthesis of prostaglandins, the signaling molecules that mediate pain and inflammation. This targeted inhibition of the inflammatory cascade provides the generalized therapeutic benefits of anti-inflammation and effective relief from pain (analgesia).

Furthermore, the drug possesses an anti-pyretic effect that assists in managing fever. This overall function makes MELOXIDYL a recognized choice for managing systemic discomfort and inflammatory processes, serving the general purpose of alleviating these core symptomatic components.

Forms and Physical Composition

MELOXIDYL is typically made available in several high-level preparations to facilitate accurate systemic administration, including tablets, an oral suspension, and an injectable solution. This variety ensures flexibility in how the active substance, Meloxicam, is delivered. These dosage forms pair Meloxicam with an appropriate base; for example, the oral suspension uses an aqueous vehicle (liquid base), while the tablet form utilizes solid excipients. This range of formulations—covering both oral and parenteral routes—is essential for achieving the required systemic effects.

Regulatory References

NIH LiverTox: Meloxicam

What side effects are possible with MELOXIDYL?

Meloxicam, the active ingredient in MELOXIDYL, is a non-steroidal anti-inflammatory drug (NSAID) which is associated with a risk of serious adverse reactions, particularly affecting the gastrointestinal tract, kidneys, and liver.

General Adverse Reactions

The most commonly reported adverse events, based on clinical studies, are gastrointestinal abnormalities such as vomiting, soft stools or diarrhea, and decreased appetite (inappetance). While these are usually mild and transient, they may occasionally be serious.

Serious and Organ-Specific Risks

As with all NSAIDs, treatment may lead to severe complications that can occur without warning and may result in death. These include:

Gastrointestinal Toxicity: Ulceration, perforation, and severe bleeding in the stomach or intestines.
Renal Toxicity: Kidney dysfunction, acute renal failure, and elevated kidney enzymes (azotemia, elevated creatinine).
Hepatic Toxicity: Liver damage, which may manifest as elevated liver enzymes (jaundice) or, rarely, idiosyncratic hepatic failure.

Critical Safety Considerations

The use of meloxicam carries specific limitations and contraindications:

Contraindications (Cats): Repeated use of meloxicam in cats is strictly contraindicated and has been explicitly associated with a high risk of acute renal failure and death. The oral suspension product is only approved for use in dogs.
Contraindications (General): The drug should not be used in patients with known hypersensitivity to meloxicam or other NSAIDs, pre-existing gastrointestinal ulceration, or bleeding disorders.
Drug Interactions: Concurrent use with other NSAIDs (including aspirin), corticosteroids (e.g., prednisone), or potentially nephrotoxic drugs (like certain diuretics) is generally advised against due to increased risk of toxicity.
At-Risk Patients: Patients who are dehydrated, elderly, or have existing cardiac, kidney, or liver dysfunction are at a significantly higher risk for developing adverse effects, particularly renal toxicity. Initial patient evaluation and regular monitoring of kidney and liver function are critical during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for MELOXIDYL (Meloxicam) overdose documents specific clinical signs and required emergency actions.

Documented Overdose Presentations

Initial overdose presentations, as described in official regulatory documents, frequently involve gastrointestinal disturbances, including nausea, vomiting, and epigastric pain. Central Nervous System effects, such as lethargy, drowsiness, and headache, are also documented. These signs mark the beginning of the toxic state.

Severe Outcomes and Required Actions

The most serious documented consequences involve systemic organ failure. These severe outcomes include the risk of acute renal failure, hepatic dysfunction, and severe gastrointestinal bleeding. In cases of high exposure, regulatory information also notes the possibility of cardiovascular collapse, respiratory depression, and convulsions.

Elderly patients are explicitly documented as being at greater risk for serious renal, cardiac, or GI complications following overdose. No specific antidote is known for Meloxicam toxicity; therefore, management described in official documentation is limited to symptomatic and supportive treatment.

For any suspected overdose, regulatory authorities mandate that individuals seek immediate medical attention or contact emergency services immediately if severe symptoms, such as collapse or seizures, are present. Procedures such as gastric lavage, administration of activated charcoal, or the use of Cholestyramine to accelerate drug clearance may be utilized as supportive measures.

Therapeutic Uses of MELOXIDYL

What MELOXIDYL Treats: Main Uses and Benefits

The medication MELOXIDYL (Meloxicam) is commonly used to help manage symptoms related to inflammatory or irritative states. The drug is considered relevant for the relief of the signs and symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA) in certain pediatric patients.

MELOXIDYL is applied across domains where additional symptomatic support is needed, particularly for conditions involving episodic or fluctuating manifestations such as chronic joint diseases, including Ankylosing Spondylitis. It is relevant for managing symptom clusters that may become intense, such as persistent pain and joint stiffness, which generally supports comfort during symptomatic periods. The medication is also relevant when supportive symptom management is appropriate during acute or episodic changes, or for easing the challenging symptoms of JIA in appropriate pediatric subgroups. Furthermore, it supports the easing of systemic imbalance by helping with fever, when fever may be part of a symptom accompanying an inflammatory condition. This supports patients during episodes of heightened discomfort.

“It is commonly used when symptoms intensify and supportive relief is needed for moderate discomfort.”

Quick Fact: Relief for Inflammatory Discomfort

Scope	Description
Primary Focus	Chronic inflammatory and degenerative joint diseases
Symptom Cluster	Pain, joint stiffness, inflammation, and associated fever
Key Benefit	Supports comfort and generally assists with symptomatic management
Use Context	Managing disease flares and long-term symptom control

Regulatory References

NIH DailyMed Meloxicam Label

Eligibility and Restrictions for Use

Who Can and Cannot Use MELOXIDYL (Meloxicam)

This medication is approved for use in adults (16 years and older) and, in certain formulations/indications, children 2 years of age and older (e.g., for Juvenile Rheumatoid Arthritis).

However, MELOXIDYL is contraindicated and must not be used by the following populations, strictly based on official regulatory labeling:

Patients with known hypersensitivity (allergy) to meloxicam or any inactive component of the drug.
Individuals who have experienced asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Patients in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery.
Women who are 30 weeks pregnant or later (third trimester).
Patients with active or a history of recurrent peptic ulcer/haemorrhage or gastrointestinal bleeding related to previous NSAID therapy.

Use is restricted or not recommended for:

Children younger than 16 years (EMA-based label) or younger than 2 years.
Patients with severe renal impairment (unless on hemodialysis, with dose limits).
Patients with severe, uncontrolled heart failure.

What should I know about interactions with other medicines?

The official interaction profile for MELOXIDYL (Meloxicam) documents clinically significant interactions primarily centered on Pharmacodynamic Risk Enhancement and Renal Clearance Modulation, as defined in government regulatory labeling.

A major contraindication exists for co-administering the oral suspension formulation with Sodium Polystyrene Sulfonate, due to the risk of intestinal necrosis. Gastrointestinal Risk Amplification is formally documented with Warfarin and other oral anticoagulants, SSRIs, SNRIs, and Corticosteroids, all of which increase the risk of serious bleeding complications. Use with Aspirin (analgesic doses) and other NSAIDs is officially restricted due to the cumulative risk of gastrointestinal adverse events.

Regarding Exposure Modification, Meloxicam's effect on renal clearance is documented to increase the plasma concentration and risk of toxicity for agents such as Lithium and Methotrexate. Conversely, Cholestyramine is noted to increase the clearance of Meloxicam, thereby reducing its systemic exposure.

Pharmacodynamic Antagonism occurs with ACE Inhibitors, ARBs, and Diuretics, whose antihypertensive and natriuretic effects may be officially diminished. This interaction carries a special caution in the elderly or volume-depleted patient populations due to a heightened risk of renal function deterioration. Finally, the co-ingestion of Alcohol or use of Tobacco is explicitly documented to amplify the risk of serious gastrointestinal bleeding.

Mechanism of Action

How MELOXIDYL works

Targeted Inhibition of the COX-2 Enzyme

This medication functions as a selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This molecular action interferes with the COX-2 dependent metabolic pathway that converts arachidonic acid into pro-inflammatory prostaglandins. Limiting the synthesis of these mediators modifies the initial chemical steps of the eicosanoid cascade, influencing the subsequent peripheral physiological response.

Dampening Chemical Signaling and Nociceptor Sensitization

The resulting reduction in specific prostaglandin levels, particularly PGE2, produces a functional change in the body's local and peripheral systems. This effect diminishes the excitability threshold of nociceptors (pain-sensing nerve endings) and reduces localized fluid exudation. This action maintains a modulated state within the targeted pathways, influencing afferent signal transmission and stabilizing local vascular dynamics without significant interference with the homeostatic functions associated with the COX-1 enzyme.

Dosage and Administration Information

Official Administration Guidelines for MELOXIDYL

MELOXIDYL (Meloxicam) administration is governed by a consistent framework that specifies the route, dose, and frequency of use to ensure standardized delivery of the active substance. The principle for use across all approved indications is to employ the lowest effective dosage for the shortest duration possible.

Dosing and Administration Parameters

Feature	Guideline
Route of Administration	Approved for oral use (tablets, suspension, capsules) and intravenous (IV) injection for short-term acute pain management.
Standard Oral Dosing	The typical starting and maintenance oral dose is 7.5 mg once daily, which may be increased to a maximum of 15 mg once daily.
IV Dosing	The recommended intravenous dose is 30 mg once daily, administered as a bolus injection.
Frequency and Timing	All standard approved regimens, both oral and IV, are administered once daily. Oral forms may be taken without regard to the timing of meals.
Population-Specific Rules	The maximum daily oral dose is restricted to 7.5 mg for patients undergoing hemodialysis. Pediatric dosing for Juvenile Idiopathic Arthritis (JIA) is calculated based on weight, not to exceed 7.5 mg once daily.
Preparation Details	The oral suspension must be gently shaken before each use. The IV bolus injection must be administered over 15 seconds.
Missed Dose Rule	If a dose is missed, it should be taken as soon as it is remembered; however, if it is almost time for the next scheduled dose, the missed dose is skipped, and two doses should not be taken at the same time.

This structured approach defines the required methods for administering the medicine, including strict adherence to the once-daily frequency and the 15 mg maximum oral dose boundary for adults, ensuring usage aligns with established standards.

Recent Clinical Evidence

MELOXIDYL: Recent Clinical Evidence

Evidence for Use in Osteoarthritis and Rheumatoid Arthritis in Adults

Research was conducted in short-term, randomized, controlled studies comparing the medication against placebo or active treatments in adult populations. Studies examined outcomes related to physical discomfort such as pain intensity and joint stiffness. For Rheumatoid Arthritis (RA), trials also monitored the ACR 20 response criterion. Research is based on controlled evidence for symptomatic endpoints; however, data largely comes from studies with limited follow-up durations, typically a few weeks to months. This means that long-term effects are not fully established.

Evidence for Use in Juvenile Rheumatoid Arthritis / Juvenile Idiopathic Arthritis (JIA)

Research for this pediatric population was evaluated in multicenter clinical trials for patients typically ages 2 to 17 years. These pediatric studies often used an active-controlled design, meaning MELOXIDYL was compared to another existing anti-inflammatory drug. The main clinical outcome studied was the measurement of the ACR pediatric 30 response criteria. The specific research design used means that comparative evidence is lacking for a direct comparison against an untreated group.

Evidence for Use in Ankylosing Spondylitis

MELOXIDYL was studied for conditions associated with acute or disruptive episodes of spinal pain in short-term placebo-controlled trials. Studies examined measures such as total pain score, functional indices (like BASFI), and the rate of achieving the ASAS20 response criteria. A key limitation is that follow-up durations were limited, typically around six weeks, which restricts information for long-term functional maintenance.

Long-Term Evidence and Durability of Response

Clinical trials primarily focused on short-term changes; evidence remains limited regarding the durability of these patterns over extended use. Some studies included extension phases that observed responses over defined time intervals up to one year or eighteen months, but these studies do not always include the control group structure of the initial trials.

What is Still Uncertain About the Research for MELOXIDYL

Key limitations include the fact that follow-up durations were limited in many controlled studies, meaning there is limited information for long-term outcomes that fully match the chronic nature of the diseases. For many specific comparisons against other treatments, comparative evidence is lacking. Furthermore, as with most clinical research, findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about MELOXIDYL (FAQ)

Q: What is the difference between MELOXIDYL and celecoxib?

Both MELOXIDYL (meloxicam) and celecoxib are classified as Non-Steroidal Anti-inflammatory Drugs ( NSAIDs). Official documentation notes that while MELOXIDYL is described as a preferential COX-2 inhibitor, celecoxib is classified as a more selective COX-2 inhibitor.

Q: How quickly should MELOXIDYL start working for joint stiffness?

The onset of full effects can vary among individuals. However, clinical studies indicate that a general clinical response is typically observed within 3 to 4 days after beginning the treatment regimen.

Q: How long do the effects of MELOXIDYL last after taking it?

This medicine is formulated for once-daily administration. This dosing frequency is supported by its elimination half-life, which is documented in official sources to be approximately 24 hours.

Q: Why do some people report swelling in their ankles or feet when taking MELOXIDYL?

Official labeling states that this medicine may lead to fluid retention and swelling, which is medically known as edema. Because of this possibility, caution is noted in official documents for individuals with existing conditions like heart failure.

Q: Does taking MELOXIDYL long-term cause any significant health issues?

Official warnings note that the risk of serious cardiovascular events (such as heart attack or stroke) and serious gastrointestinal events (including bleeding or ulceration) is observed to increase with the duration of use.

Q: Are there published studies about MELOXIDYL and heart health?

Regulatory documents include a Boxed Warning addressing the potential for serious cardiovascular thrombotic events. Furthermore, the medicine is contraindicated—meaning it should not be used—following coronary artery bypass graft ( CABG) surgery.

Q: Why is MELOXIDYL only available by prescription?

This medicine is designated as Prescription-only ( Rx) because of its potential for serious side effects, including cardiovascular, gastrointestinal, and renal risks. These potential serious outcomes necessitate healthcare provider supervision and regular medical monitoring.

Q: Is it normal to feel dizzy or sleepy after starting MELOXIDYL?

Official information documents drowsiness and dizziness as effects on the Central Nervous System that may occur. Official guidance suggests that caution should be exercised regarding activities such as driving if these side effects occur.

Q: Does MELOXIDYL affect blood pressure?

Official warnings state that the use of this medicine may lead to the new onset or worsening of high blood pressure ( hypertension). Because of this, close monitoring of blood pressure is recommended during the course of treatment.

Q: Are there specific vitamins or supplements that interact with MELOXIDYL?

Regulatory information notes that certain nonprescription medicines and dietary supplements may interact. Supplements that have potential blood-thinning properties (such as Garlic or Ginkgo biloba) are specifically mentioned as potentially increasing the risk of bleeding.

Q: Does MELOXIDYL thin the blood?

Studies show that it does not significantly decrease platelet function or increase bleeding time in healthy subjects. However, regulatory information states that co-administration with blood-thinning drugs is noted to increase the overall risk of bleeding.

Q: Can MELOXIDYL be used for headaches or migraines?

Traditional formulations of meloxicam are approved for chronic inflammatory conditions like arthritis. However, a distinct combination product that includes meloxicam has received regulatory approval specifically for the treatment of acute migraine headaches.

Q: Does MELOXIDYL interact with common over-the-counter cold and flu medicines?

Regulatory guidance advises caution against combining this medication with other NSAIDs ( Non-Steroidal Anti-inflammatory Drugs). Other NSAIDs are frequently present as active ingredients in over-the-counter cold and flu medicines, and taking them together increases the risk of serious gastrointestinal events.

Q: Does MELOXIDYL cause weight gain or loss?

Official documentation notes that rapid weight gain may occur as a symptom associated with water retention or swelling ( edema), which is listed as a potential side effect of the medicine.

Q: Can MELOXIDYL affect fertility in men or women?

As a member of the NSAID class of medications, official documents state it is generally not recommended for use in women attempting to conceive because it may impair female fertility.

Q: Does the official information recommend monitoring liver function while taking MELOXIDYL?

Yes, official regulatory warnings address the risk of liver damage ( Hepatotoxicity). Supervision includes the recommendation for monitoring liver function in patients who have existing hepatic (liver) impairment.

Q: Is the onset of relief faster with liquid or tablet forms of MELOXIDYL?

Bioequivalence studies that compare the different formulations at steady-state show that the absorption profiles ( AUC and Cmax) of the oral suspension (liquid) and tablets are generally comparable.

Q: Will MELOXIDYL interfere with driving or operating machinery?

Official patient information explicitly advises caution regarding driving or operating machinery. This warning applies if the medicine causes side effects such as drowsiness, dizziness, or light-headedness.

Q: Is MELOXIDYL a controlled substance?

Official status indicates that this medicine is a prescription Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a controlled substance under federal or international drug scheduling.

How should MELOXIDYL be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory documents define the required conditions for storing and disposing of MELOXIDYL (meloxicam oral suspension).

Item	Official Regulatory Statement
Storage Temperature	Controlled Room Temperature (often 15 to 30 C or 59 to 86 F), or no special storage conditions required (EU SmPC).
Stability After Opening	The product must be used within 6 months after the immediate packaging is first opened (EU SmPC).
Handling Requirements	The suspension must be shaken well before every use and contamination must be avoided during use.
Child Safety	Keep out of the reach and sight of children. Do not leave an unattended filled syringe where children can access it.
Disposal	Unused product and waste materials must be disposed of in accordance with local requirements and should not be disposed of via wastewater or household waste. Any uneaten medicated food must be disposed of immediately.